BioLineRx (BLRX) Total Non-Current Liabilities (2021 - 2025)

BioLineRx has reported Total Non-Current Liabilities over the past 5 years, most recently at $5.4 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $5.4 million for Q4 2025, down 45.84% from a year ago — trailing twelve months through Dec 2025 was $5.4 million (down 45.84% YoY), and the annual figure for FY2025 was $5.4 million, down 45.84%.
  • Total Non-Current Liabilities for Q4 2025 was $5.4 million at BioLineRx, down from $10.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for BLRX hit a ceiling of $14.9 million in Q4 2022 and a floor of $3.6 million in Q4 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $7.9 million (2023), compared with a mean of $8.4 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 314.62% in 2022 and later tumbled 46.73% in 2023.
  • BioLineRx's Total Non-Current Liabilities stood at $3.6 million in 2021, then soared by 314.62% to $14.9 million in 2022, then tumbled by 46.73% to $7.9 million in 2023, then rose by 26.79% to $10.0 million in 2024, then tumbled by 45.84% to $5.4 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $5.4 million (Q4 2025), $10.0 million (Q4 2024), and $7.9 million (Q4 2023) per Business Quant data.